Abstract

Obesity often causes systemic metabolic disorders in close association with adipose tissue dysfunction. Adipose tissue contains well-developed vasculatures, and obesity mediates vascular rarefaction that causes hypoxia and triggers inflammation in adipose tissue. Adipose tissue-derived neuregulin-4 (Nrg4) is an immerging factor that is critically involved in metabolic homeostasis. We recently identified that Nrg4 is an angiogenic adipokine that plays an important role in maintaining adipose tissue vasculature. Here, we further validated its beneficial role in metabolic health primarily by enhancing adipose tissue angiogenesis. Targeted activation of Nrg4 in adipocytes improved metabolic health in mice under both normal and high fat dietary condition without changes in body weight. Activation of Nrg4 increased blood vessels in white adipose tissue, and ameliorated adipose tissue hypoxia under obese condition. Of note, inhibition of angiogenesis by sugen-treatment abolished the beneficial effects of Nrg4 on systemic metabolic health. Furthermore, targeted inhibition of Nrg4-ErbB signaling in adipose tissue vasculature using prohibitin binding peptide-conjugated nanocarrier abrogated the enhanced adipose tissue angiogenesis, and canceled the improved metabolic health induced by Nrg4 activation. These data further support a crucial role of Nrg4 in maintaining systemic metabolic homeostasis at least partially through enhancing adipose tissue angiogenesis.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.